X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/biogen-notches-another-tecfidera-patent-win-europe-ec-blocks-generics-mylan-teva-and-more
https://www.prnewswire.com/news-releases/european-commission-revokes-all-centrally-granted-generic-marketing-permissions-for-dimethyl-fumarate-dmf-including-dimethyl-fumarate-neuraxpharm-302020027.html
https://endpts.com/biogen-finally-scores-win-in-fight-to-prevent-copycats-of-multiple-sclerosis-drug-tecfidera-in-eu/
https://investors.biogen.com/news-releases/news-release-details/biogen-receives-favorable-decision-court-justice-european-union#:~:text=With%20this%20favorable%20decision%2C%20Biogen,TECFIDERA%2C%20which%20expires%20in%202028.
https://www.europeanpharmaceuticalreview.com/news/177879/stem-cell-transplants-may-slow-disability-progression-in-ms/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210385
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210414
https://www.fiercepharma.com/pharma/supreme-court-swats-down-biogens-last-gasp-effort-reinstate-tecfidera-patent
https://www.fiercepharma.com/pharma/biogen-pays-900m-resolve-ms-drugs-doctor-kickback-whistleblower-suit-competition-mounts
https://www.fiercepharma.com/pharma/biogen-gains-american-chemical-societys-backing-bid-supreme-court-review-tecfidera-patent
https://www.globenewswire.com/news-release/2022/06/21/2465918/0/en/European-Patent-Office-Grants-Patent-Related-to-TECFIDERA-Dimethyl-Fumarate.html
https://www.ema.europa.eu/en/documents/overview/dimethyl-fumarate-polpharma-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/dimethyl-fumarate-neuraxpharm-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/biogens-tecfidera-patent-contingency-plan-falls-flat
https://www.prnewswire.com/news-releases/viatris-wins-federal-circuit-court-appeal-upholding-district-court-decision-invalidating-biogens-tecfidera-patent-301434839.html
https://investors.biogen.com/news-releases/news-release-details/biogen-grows-presence-china-approval-tecfiderar-dimethyl
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210436
https://www.biopharmadive.com/news/biogen-is-running-out-of-safety-nets/587481/
https://www.prnewswire.com/news-releases/abarca-details-first-value-based-agreement-for-medicaid-members-prescribed-biogen-products-301156036.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210226
https://www.bloomberg.com/press-releases/2020-10-07/glenmark-pharmaceuticals-receives-anda-approval-for-dimethyl-fumarate-delayed-release-capsules-120-mg-and-240-mg
https://www.moneycontrol.com/news/business/stocks/glenmark-pharma-share-price-rises-on-final-usfda-approval-for-a-generic-5931601.html
https://www.business-standard.com/article/news-cm/dr-reddys-labs-launches-tecfidera-generic-in-us-market-120092600629_1.html#:~:text=The%20drug%20major%20on%2026,and%20Drug%20Administration%20(USFDA).
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-launches-generic-drug-to-treat-multiple-sclerosis-in-us/articleshow/78333782.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.cipla.com/press-releases-statements/cipla-approval-generic-version-biogen-idec-incs-tecfidera-dimethyl-fumarate-capsules
https://www.business-standard.com/article/markets/cipla-surges-5-on-ufda-approval-for-dimethyl-fumarate-dr-capsules-120092500551_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210305
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210402
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210440
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210460
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210499
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210500
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210538
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-us-health-regulator-nod-for-multiple-sclerosis-treatment-drug/articleshow/78309972.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.fiercepharma.com/pharma/roche-s-ocrevus-touts-2-year-switching-data-jam-packed-and-growing-multiple-sclerosis
https://www.biopharmadive.com/news/mylan-biogen-tecfidera-generic-launch/583793/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210531
https://endpts.com/mylan-wins-an-early-fda-ok-for-a-tecfidera-knockoff-with-biogens-blockbuster-franchise-hanging-in-the-balance/
https://endpts.com/biogens-last-ditch-injunction-to-protect-tecfidera-is-denied-paving-way-for-mylan-generic/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-15-1595071335.pdf
https://www.fiercepharma.com/marketing/looking-to-capitalize-biogen-s-tecfidera-patent-loss-mylan-faces-a-fork-road-generic
https://www.fiercepharma.com/pharma/heads-up-biogen-after-digging-into-tecfidera-patent-litigation-analyst-predicts-a-loss
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210460
https://www.reuters.com/article/us-biogen-multiple-sclerosis-mylan/u-s-patent-office-rules-in-favor-of-biogen-over-mylan-for-ms-drug-idUSKBN1ZZ2OJ?feedType=RSS&feedName=healthNews
https://www.fiercepharma.com/pharma/biogen-wins-tecfidera-patent-challenge-from-mylan-sending-shares-way-up
https://www.bloomberg.com/news/articles/2020-02-03/biogen-investors-face-next-test-with-pending-drug-patent-ruling
Market Place
Share 
